15.07.2020 SARTORIUS AG  DE0007165607

DGAP-Adhoc: SARTORIUS AG: Sartorius raises forecast for the full year of 2020


DGAP-Ad-hoc: SARTORIUS AG / Key word(s): Change in Forecast
SARTORIUS AG: Sartorius raises forecast for the full year of 2020

15-Jul-2020 / 18:37 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of inside information according to Article 17 MAR

Sartorius raises forecast for the full year of 2020

- Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group; outlook for the Lab Products & Services Division unchanged

Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Group. Management now expects consolidated sales revenue to increase by 22% to 26% (previously 15% to 19%) and the Group's underlying EBITDA margin1 to reach about 28.5% (previously about 27.5%). Upward revision of this forecast is partly due to the current coronavirus pandemic as Sartorius products are used for manufacturing both vaccines and antiviral medications.

For the Bioprocess Solutions Division, management now forecasts sales growth of 26% to 30% (previously 17% to 21%) and an underlying EBITDA margin1 of approximately 31% (previously around 30%). The outlook for Lab Products & Services remains unchanged, with sales revenue expected to grow by 10% to 14% at an underlying EBITDA margin1 of approximately 20% (all forecasts are based on constant currencies as in the past).

Due to the ongoing pandemic, this guidance is subject to greater uncertainty than usual. In particular, these updated projections are based on the assumptions that logistics chains will continue to be stable and production lines remain in operation.

In the first half of 2020, the Sartorius Group increased its order intake2 according to preliminary figures by 27.5% in constant currencies. Its sales revenue rose by 17.9% at an underlying EBITDA margin1 of 27.8%.

Sartorius will publish its complete first-half report on July 21, 2020, as planned. A conference call for investors and analysts will be held on the same day at 3:30 pm CEST.

1 Underlying EBITDA: Earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
2 Order intake: All customer orders contractually concluded during the respective reporting period

Göttingen, July 15, 2020

This notification according to Article 17 MAR contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language announcement. The Sartorius Group shall not assume any liability for the correctness of this translation. The original German ad hoc announcement is the legally binding version. Furthermore, the Sartorius Group reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
[email protected]

15-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Otto-Brenner-Straße 20
37079 Göttingen
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: [email protected]
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1094719

End of Announcement DGAP News Service

1094719  15-Jul-2020 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 275,500 Halten 23.482,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 39,18 1,15 63,35
10,23 24,17 6,92 26,55
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
1,43 0,73 0,26 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,43% 6,92% 3,96% -13,91%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen

Medtech , 716560 , SRT , XETR:SRT